Prof. Dr. Mutlu Demiray

Mezun Olduğu Tıp Fakültesi ve Yılı

Akdeniz Üniversitesi Tıp Fakültesi, 1995

Uzmanlık Eğitimi Aldığı Yer ve Yılı

Uludağ Üniversite Tıp Fakültesi, 2005

İç Hastalıkları, 2000

Tıbbi Onkoloji, 2004

Mesleki Deneyim

Medicana Sağlık Grubu (Prof. Dr.), 2014 - Halen

Almanya İntegratif Onkoloji Eğitimi, Serbest Hekimlik (Doç. Dr.), 2013 - 2014

OSM Ortadoğu Hastanesi (Doç. Dr.), 2011 - 2013

İstanbul İtalyan Hastanesi (Doç. Dr.), 2010 - 2011

Medical Park Bursa Hastanesi (Doç. Dr.), 2007 - 2010

Ali Osman Sönmez Onkoloji Hastanesi (Doç. Dr.), 2006 - 2007

Uludağ Üniversitesi (Uzm. Dr.), 2004 - 2006

DNA Repair Deficiency: A Series of 8 Patients. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420969812. doi: 10.1177/1534735420969812. PMID: 33150793.

A2. Bahadori F, Demiray M. Management of extravasation of oxaliplatin by mimicking its biotransformation. Clin Transl Oncol. 2018 Oct;20(10):1353-1357. doi: 10.1007/s12094-018-1854-z. Epub 2018 Apr 27. PMID: 29704231.

A3. Sahinbas H, Rosch M, Demiray M. Temperature measurements in a capacitive system of deep loco-regional hyperthermia. Electromagn Biol Med. 2017;36(3):248-258. doi: 10.1080/15368378.2017.1307221. Epub 2017 Apr 27. PMID: 28448752.

A4. Bahadori F, Demiray M. A Realistic View on "The Essential Medicinal Chemistry of Curcumin". ACS Med Chem Lett. 2017 Sep 14;8(9):893-896. doi: 10.1021/acsmedchemlett.7b00284. PMID: 28947929; PMCID: PMC5601379.

A5. Demiray M, Sahinbas H, Atahan S, Demiray H, Selcuk D, Yildirim I, Atayoglu AT. Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report. Complement Ther Med. 2016 Aug;27:108-13. doi: 10.1016/j.ctim.2016.06.009. Epub 2016 Jul 1. PMID: 27515884.

A6. Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014 Oct;22(10):2629-34. doi: 10.1007/s00520-014-2253-9. Epub 2014 Apr 22. PMID: 24752566; PMCID: PMC4153980.

A7. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006 Nov;24(7):669-76. doi: 10.1080/07357900600981307. PMID: 17118776.

A8. Demiray M, Kurt E, Evrensel T, Kanat O, Arslan M, Saraydaroglu O, Ercan I, Gonullu G, Gokgoz S, Topal U, Tolunay S, Tasdelen I, Manavoglu O. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer Invest. 2005;23(5):386-91. doi: 10.1081/cnv-67133. PMID: 16193637.

A9. Demiray M, Gulten M, Manavoglu O, Evrensel T, Ulukaya E, Yerci O, Kanat O, Kurt E, Arslan M, Gonullu G, Demiray H, Gulten T, Memik F. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study. Hepatogastroenterology. 2004 Sep-Oct;51(59):1531-5. PMID: 15362794.

A10. Gulten T, Tokyay N, Demiray M, Gulten M, Ercan I, Evke E, Sardas S, Karakaya AE. The role of triple therapy, age, gender and smoking on the genotoxic effects of Helicobacter pylori infection. J Int Med Res. 2002 Jul-Aug;30(4):380-5.

A11. Arslan M, Evrensel T, Kurt E, Demiray M, Ercan I, Kanat O, Ozkan A, Manavoglu O. Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients. Neoplasma. 2005;52(1):43-5.

A12. Arslan M, Evrensel T, Kurt E, Demiray M, Gonullu G, Kanat O, Manavoglu O. Comparison of clinical outcomes of different erythropoietin usage strategies. Tumori. 2004 Jul-Aug;90(4):394-8.

A13. Kanat O, Evrensel T, Kurt E, Demiray M, Gonullu G, Arslan M, Manavoglu O. Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori. 2004 Mar-Apr;90(2):192-5.

A14. Kanat O, Evrensel T, Manavoglu O, Demiray M, Kurt E, Gonullu G, Kiyici M, Arslan M. Single agent irinotecan as second-line treatment for advanced gastric cancer. Tumori. 2003 Jul-Aug;89(4): 405-7.

A15. Kanat O, Adim S, Evrensel T, Yerci O, Ediz B, Kurt E, Demiray M, Gonullu G, Arslan M, Manavoglu O.Prognostic value of nm23 in gastrointestinal stromal tumors. Med Oncol. 2004; 21(1): 53-8.

A16. Kurt E, Sezgin C, Evrensel T, Yalcinkaya U, Kanat O, Veral A, Demiray M, Arslan M, Karabulut M, Ercan I, Goker E, Manavoglu O. Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary carcinoma Int J Clin Pract. 2005 May;59(5):537-43.

A17. Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, Kurt E, Demiray M, Gonullu G, Manavoglu O. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol. 2003;20(3):237-45.

A18. Kanat O, Evrensel T, Adim SB, Yavascaoglu I, Kurt E, Demiray M, Gonullu G, Manavoglu O. Small cell carcinoma of the urinary bladder. A clinicopathologic study of five cases. Tumori. 2003 MayJun;89(3):328-30.

A19. Alper E, Gurel M, Evrensel T, Ozkocaman V, Akbunar T, Demiray M.99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy. Nucl Med Commun. 2003 May;24(5):537-42.

A20. Kanat O, Evrensel T, Demiray M, Kurt E, Gonullu G, Arslan M, Manavoglu O, Ozkan A. Cisplatin plus etoposide in advanced non-small cell lung cancer patients age of 70 years or older. Lung Cancer. 2003 Aug;41(2):233-4.

A21. Kanat O, Evrensel T, Kurt E, Arslan M, Demiray M, Aker S, Manavoglu O. Successful treatment of thymoma-associated erythroid hypoplasia and thrombocytopenia with paclitaxel. Clin Oncol (R Coll Radiol). 2005 Feb;17(1):68

A22. Tasdelen I, Gokgoz S, Paksoy E, Yerci O, Cetintas SK, Demiray M, Samsa V. Acquired lymphangiectasis after breast conservation treatment for breast cancer: report of a case. Dermatol Online J. 2004 Jul 15;10(1):9.

A23. Ozkan K, Turkkan E, Ender K, Mutlu D, Murat A, Nalan B, Abdulmecit Y, Osman M. 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients. Indian J Cancer. 2005 Apr-Jun;42(2):85-8.

B. Uluslararası Bilimsel Toplantılarda Sunulan ve Bildiri Kitaplarında (Proceedings) Basılan Bildiriler

B1. Disel U, Kose F, Bilici A, Özgüroğlu M, Saglam S, Seker M, Aksoy S, Tek I, Eralp Y, Mandel NM, Demir G, Arslan C, Demiray M, Salepci T, Ozturk MA, Biricik FS, Temizas G, Fidan EG. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study. Journal of Clinical Oncology 38 (15_suppl), e13646-e13646. 2020/5/20

B2. Can Curcumin be Employed to Promote the Integration of Oncology and Natural Products? Demiray M, Bahadori F. Proceedings 2017, 1(10), 980.

B3. Sevim B. B. , Çerçi B. H. , Küçük Z., BAHADORİ F., Kazdal F., Eskandari Z., Tırıs G., DEMIRAY M. Optimization of a new controlled release oral dexketoprofen formulation. 24th World Nano Conference, Roma, İtalya, 07 May 2018, ss.1

B4. Demiray M. Can Curcumin overcome cancer chemoresistance. 5th International Meeting on Complementary & Alternative Medicine and Therapies September 18-19, 2017 Charlotte, USA

B5. Demiray M. CURCUMIN: A potential new therapeutic option in Head & Neck Carcinoma. BIT's 10th Annual World Cancer Congress -2017 (WCC-2017) will be held on 19-21, May 2017 in Barcelona, Spain.

B6. Demiray M, Sahinbas H. Hyperthermia , Chemotherapy and Curcumin treatment modality is safe and may be more effective strategy for cancer treatment. V. Hyperthermia Symposium Köln 3-4 october 2015

B7. Demiray M, Manavoglu O, Evrensel T, Tasdelen I, Tolunay S, Kurt E, Kanat O, Gonullu G. The response rates of two different dosages of epirubicin in neoadjuvant chemotherapy of locally advanced breast cancer: High dose vs low dose ? ASCO 2003 Proc Am Soc Clin Oncol 22: page 81, 2003 (abstr 322)

B8. Demiray M, Gülten M, Kurt E, Evrensel T, Kanat O, Ulukaya E, Gonullu G, Manavoglu O. Relationship of Helicobacter Pylori status and gastric epithelial proliferation. 11th World Congress of surgeons&gastroenterologists, Hepato-Gastroenterology, 2001;48(suppl 1): p108.

B9. Demiray M, Kurt E, Gülten M, Evrensel T, Kanat O, Izgi B, Gonullu G, Manavoglu O.Relationship of Helicobacter Pylori status and serum selenium and malondialdehyde levels. 11th World Congress of surgeons&gastroenterologists, Hepato-Gastroenterology, 2001;48(suppl 1): p109.

B10. Gonullu G, Kurt E, Evrensel T, Demiray M, Kanat O, Yilmazlar T, Manavoglu O. Our treatment results of rectum melanoma. 11th World Congress of surgeons&gastroenterologists, HepatoGastroenterology 2001;48(suppl 1): p144.

B11. Gonullu G, Kurt E, Evrensel T, Kanat O, Demiray M, Yerci O, Manavoglu O Primary gastric lymphomas: Clinical features and results of therapy.. 11th World Congress of surgeons&gastroenterologists, Hepato-Gastroenterology 2001;48(suppl 1): p145.

B12. Kanat O, Kurt E, Evrensel T, Demiray M, Gonullu G, Manavoglu O. Malignant gastrointestinal tumors: Clinical features and results of therapy. 11 t h Wo r l d C o n g r e s s o f surgeons&gastroenterologists, Hepato-Gastroenterology 2001;48(suppl 1): p142.

B13. Kurt E, Kanat O, Evrensel T, Demiray M, Arslan M, Gonullu G, Manavoglu O. A phase II study of gemcitabine plus 5-fluorouracil in patients with advanced pancreatic cancer. 11th World Congress of surgeons&gastroenterologists, Hepato-Gastroenterology 2001;48(suppl 1): p132.

B14. Kurt E, Evrensel T, Dilek K, Filiz G, Gonullu G, Kanat O, Arslan M, Demiray M, Manavoglu O. Effects of two different doses of recombinant human erythropoietin (rHuEPO) on cisplatin-induced acute renal failure. Program/Proceedings, ASCO-Thirty-Eighth Annual Meeting, May 18-21, 2002, Orlando, FL, P1842.

B15. Arslan M, Kurt E, Evrensel T, Gonullu G, Kanat O, Demiray M, Ali R, Manavoglu O. Comparison of the serum erythropoietin levels in chemotherapy-naïve and cisplatin-treated cancer patients. 27th ESMO Congress, 18-22 October, 2002, Nice-France. P73.

B16. T. Gulten, M. Demiray M, İ. Ercan, M.Gülten, R. Tokyay. Standart eradication therapy reduces the DNA damage in Helicobacter pylori infected patient. Eurosurgery 2000, İstanbul, 2000

B17. Kurt E, Demiray M, Kanat O, Evrensel T, Arslan M, Gonullu G, Yilmazlar T, Manavoglu O. Gastrointestinal cancers associated with other primary cancers. 11th World Congress of surgeons&gastroenterologists, Hepato-Gastroenterology 2001;48(suppl 1): p133.

B18. Gonullu G, Kurt E, Evrensel T, Kanat O, Demiray M, Tasdelen I, Manavoglu O. Neoadjuvant chemotherapy for breast cancer: Results of a single institute experience. 27th ESMO Congress, 18-22 October, 2002, Nice-France. P226

B19. Kanat O, Kurt E, Evrensel T, Demiray M, Ozkan A, Gonullu G, Manavoglu O. Fluorouracil, Epirubicin and Cisplatin (FEP) in locally advanced or metastatic gastric cancer. 12th World Congress of International Association of Surgeons&Gastroenterologists, October 30-November 2, 2002, Istanbul. PP339.

B20. Gonullu G, Kurt E, Evrensel T, Kanat O, Demiray M, Manavoglu O. Clinical features and treatment result of gastrointestinal system (GIS) lymphoma. 12th World Congress of International Association of Surgeons&Gastroenterologists, October 30-November 2, 2002, Istanbul. PP353.

B21. Gonullu G, Kurt E, Evrensel T, Demiray M, Kanat O, Manavoglu O. FEP regimen in the treatment of hepatocellular and biliary tract carcinoma. 12th World Congress of International Association of Surgeons&Gastroenterologists, October 30-November 2, 2002, Istanbul. PP348.

B22. Gonullu G, Kurt E, Evrensel T, Kanat O, Demiray M, Arslan M, Kiyici M, Yilmazlar T, Manavoglu O. Second-Line 5-fluorourocil+folinic acid+irinotecan chemotherapy in colorectal cancer patients. 12th World Congress of International Association of Surgeons&Gastroenterologists, October 30November 2, 2002, Istanbul. PP347.

B23. Tuna Gülten, Tokyay N, Demiray M, Ercan I, Evke E, Gülten M, Sardas S, Karakaya E.A. The role of age, gender and smoking on helicobacter pylori’s genetoxic effect and on the efficacy of the eradication therapy. Europan Human Genetics Conference 2000.

B24. Yakut T, Demiray M, Çalışkan Z, Gülten T. HER2/neu gene amplification in muscle invasive bladder cancer; FISH analysis on paraffin-embedded specimens. EUROPEAN HUMAN GENETICS CONFERENCE 2005 Center, Prague, Czech Republic May 7 - 10, 2005. P0533.

B25. Demiray M, Evrensel T, kanat O, Kurt E, Arslan M, Gokgoz S, Manavoglu O. Open labeled phase II observation study of gemcitabine plus cisplatin plus trastuzumab (GCT) in metastatic breast cancer patients with prior anthracyclines and taxanes exposures: Preliminary results. Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006) 10720-10720.

B26. Camcı C, Demiray M, Szekely C, M.A Chavez-Zamudio, Kral A, Weitckus S, Soldatenkova V, Benhadji K. Effectiveness Of Taxane Monotherapy (TM) and Taxane combination (TC) treatment in patients with advanced breast cancer. Annals of Oncology 2010 vol 21 sump. 8.

C. Yazılan Ulusal/Uluslararası Kitaplar veya Kitaplardaki Bölümler

C1. Yazılan Ulusal/Uluslararası Kitaplardaki Bölümler

C1.1. Meme kanserleri. Editörler: Engin K, Çetintaş SK. 2005 Nobel Tıp Kitap Evleri. ISBN:975-420-416-0. Meme Kanserinde Hormonal Regülasyon, Steroid reseptörleri ve hormonal tedaviye direnç. Sayfa 75-81. Mutlu Demiray.

2. Klinik Onkoloji El Kitabı (Manual Of Clinical Oncology) Çeviri Editörü: Osman manavoğlu. Palme Yayınları. ISBN:975-8624-87-3

Kanser kemoterapi ajanları sayfa 48-96 Mutlu Demiray.

Sarkomlar sayfa 349-363. Mutlu Demiray.

Primeri bilinmeyen metastazlar sayfa 381-399. Mutlu Demiray, Murat Arslan.

3. C vitamini ve Kanser. Çeviri Editörü Mutlu Demiray

D. Ulusal Hakemli Dergilerde Yayımlanan Makaleler

D1. Demiray M, Evrensel T, Arslan M, Kanat O, Kurt E, , Saraydaroglu O, Ercan I, Gokgoz S, Topal U, Tolunay S, Tasdelen I, Manavoglu O. Phase II study of gemcitabine plus epirubicin plus paclitaxel in metastatic breast cancer patients. Turkish Journal Of Cancer 2005, Volume 35, Number 4, Page(s) 159-165

D2. Demiray M, Evrensel T, Kanat O, Kurt E, Arslan M, Saraydaroglu O, Ercan I, Gonullu G, Gokgoz S, Tolunay S, Gozkaman A, Akgul N, Tasdelen I, Manavoglu O. The Efficacy Of Two Different Dosages Of Epirubicin In Neoadjuvant Setting: Fec50 Vs Fec100.Preliminary Report. Turkish Journal Of Cancer 2005, Volume 35, Number 1, Page(s) 019-025

D3. Demiray M, Manavoğlu O. Helicobacter pylori ve gastrik karsinogenez. Uludağ Üniversitesi Tıp Fakültesi Dergisi 29 (2) 29-33, 2003.

D4. Kurt E, Evrensel T, Dilek K, Gönüllü G, Kanat Ö, Demiray M, Arslan M, Ünlü Ö, Manavoğlu O. Cisplatin’e bağlı böbrek toksisitesi ve sentetik oral prostaglandin E1 analoğunun etkinliğinin değerlendirilmesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi 28(2):17-20,2002

D5. Kanat Ö, Evrensel T, Kurt E, Demiray M, Arslan M, Gönüllü G, Babacan N, Yıldız A, Manavoğlu O. 5-Fluorouracil, epirubicin, and cisplatin (FEP) in the treatment of gastric carcinoma. Turkish Journal of cancer 2004, Volume 34, Number 3, Page(s) 122-126

D6. Kanat Ö, Evrensel T, Bayram S, Tolunay Ş, Kurt E, Demiray M, Gönüllü G, Kahvecioğlu S, Gebitekin C, Manavoğlu O. Timoma: On bir olgunun retrospektif analizi. Bursa Devlet Hastahanesi Bülteni 18(1): 19-23, 2002

D7. Gönüllü G, Erdoğan C, Evrensel T, Kurt E, Demiray M, Arslan M, Kanat Ö, Ursavaş A, Gözkaman A, Manavoğlu O. Vena kava süperior sendromunda endovasküler tedavi yönteminin etkinliği. Bursa Devlet Hastahanesi Bülteni 19(3): 139-143, 2004

D8. Gönüllü G, Evrensel T, Kurt E, Bayram S, Demiray M, Kanat Ö, Arslan M, Gözkaman A, Altundal Y, Manavoğlu O. Evre III Küçük hücreli dışı akciğer kanserinde (KHDAK) neoadjuvant gemsitabin ve sisplatin kombinasyonunun etkinliğinin değerlendirilmesi. Bursa Devlet Hastahanesi Bülteni 19(1): 31-34, 2004

D9. Kanat O, Evrensel T, Tolunay S, Demiray M, Gönüllü G, Kurt E, Manavoğlu O. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: Description of a case and review of the literature. 2004, Volume 34, Number 3, Page(s) 122-126

D10. Kanat Ö, Evrensel T, Demiray M, Gönüllü G, Kurt E, Filiz G, Manavoğlu O. Uzun süreli tam remisyondaki küçük hücreli mesane karsinomlu olguda izole beyin metastazı. THOD 2003, vol 13, num 3 page(s): 153-156

D11. Kurt E, Evrensel T, Arslan M, Filiz G, Gönüllü G, Kanat Ö, Demiray M, Manavoğlu O. Eş zamanli olarak saptanan dört primer kanserli olgu. THOD 2002, Vol 12, Num 3 Page(s): 157-161

D12. Gönüllü G, Evrensel T, Kurt E, Kanat O, Demiray M, Arslan M, Yılmazlar S, Yalçın R, Adım Ş, Gözkaman A, Manavoğlu O. İntrakraniyal yerleşimli germ hücreli tümör olgusu. Bursa Devlet Hastanesi Bülteni 2004 19(2) s99-104

D13. Gönüllü G, Kurt E, Evrensel T, Adım Ş, Demiray M, Kanat O, Özgüç H, Manavoğlu O. Rektum kanseri ve cilt metastazı. Bursa Devlet Hastanesi Bülteni 2002 18(1) s57-62

E. Ulusal Bilimsel Toplantılarda Sunulan ve Bildiri Kitaplarında Basılan Bildiriler

E1. Demiray M, Ulukaya E, Arslan M, Yılmaztepe A, Saraydaroğlu Ö, Gökgöz Ş, Evrensel T, Manavoğlu O. Serum apoptosis düzeyi meme kanserinin neoadjuvan kemoterapiye yanıtında markır olabilirmi? XVI. Ulusal Kanser Kongresi Antalya 2005

E2. Demiray M, Evrensel T, Gökgöz Ş, Arslan M, Saraydaroğlu Ö, Topal U, Taşdelen İ, Manavoğlu O.Neoadjuvan FEC ile Epirubisin+Dozetaksel kombinasyonlarının etkinliğinin karşılaştırılması: Prospektif Randomize çalışma. XVI. Ulusal Kanser Kongresi Antalya 2005

E3. Demiray M, Manavoğlu O, Evrensel T, Taşdelen İ, Tolunay Ş, Kurt E, Kanat O, Gönüllü G. Meme kanserinin neoadjuvan kemoterapisinde antrasiklin doz intensitesi cevabı etkiliyor mu? XV. Ulusal Kanser Kongresi Antalya, 2003.

E4. Ediger D, Demiray M, Uzaslan E, Karadağ M, Yüksel EG, Özyardımcı N. Atipik pnömoni ile ortaya çıkan yaygın değişken immune yetmezlik sendromu olgusu. 25. Yıl Akciğer Günleri 2000. .

E5. Demiray M, Evrensel T, Kanat O, Gebitekin C, Kurt E, Gönüllü G, Demiray H, Manavoğlu O. Sistemik Sitotoksik ve non-sitotoksik tedavi ile cevap alınan desmoid tümör olgusu. Ulusal Kanser kongresi Antalya 2003 Bildiri Özetleri S177 (P1501)

E6. Demiray M, Demiray H, evrensel T, Kurt E, Kanat Ö, Gönüllü G, Akıncıoğlu Ç, Akbunar T, Manavoğlu O. Meme kanserindeki kemik metastazlarında alkalen fosfatazın prediktif değeri. Ulusal Kanser kongresi Antalya 2003 Bildiri Özetleri S134 (P362).

E7. Süleymanlar İ, Altınayak R, Demiray M, Özben T, Işıtan F. Kronik karaciğer hastalıklarında parankim hasarının göstergesi olarak plazma fibronektin düzeyi. XI. Ulusal Türk gastroenteroloji Kongresi 1994 Antalya

E8. Kanat Ö, Kurt E, Evrensel T, Arslan M, Gönüllü G, Demiray M, Manavoğlu O. NSCLC olgularında sekond line kemoterapi sonuçlarımız. Ulusal Kanser kongresi İstanbul 2001 Bildiri Özetleri S74 (SB10)

E9. Gönüllü G, Evrensel T, Kurt E, Kanat O, Demiray M, Arslan M, Manavoğlu O. Lokal ileri meme kanserinde primer kemoterapi sonuçlarımız. Ulusal Kanser kongresi İstanbul 2001 Bildiri Özetleri S118 (PO-1ME)

E10. Kurt E, arslan M, Evrensel T, Demiray M, Kanat O, Gönüllü G, Manavoğlu O. Multipl primer kanserli hastalarımızın analizi. Ulusal Kanser kongresi İstanbul 2001 Bildiri Özetleri S131 (PO-4)

E11. Evrensel T, Kanat O, Kurt E, Gönüllü G, Demiray M, Manavoğlu O. Primer gastrik lenfomalı hastalarımızın analizi. Ulusal Kanser kongresi İstanbul 2001 Bildiri Özetleri S186 (PO-5)

E12. Evrensel T, Kurt E, Kanat O, Gönüllü G, Demiray M, Arslan M, Yılmazlar T, Öztürk H, Manavoğlu O. Primer karaciğer lenfoması: Vaka sunumu. Ulusal Kanser kongresi İstanbul 2001 Bildiri Özetleri S186 (PO-5)

E13. Kanat O, evrensel T, Özkan A, Demiray M, Kurt E, Gönüllü G, Manavoğlu O. Yetmiş yaş üzeri küçük hücreli dışı akciğer kanserli olgulada cisplatin ve etoposide kombinasyon tedavisinin etkinliği. Ulusal Kanser kongresi Antalya 2003 Bildiri Özetleri S23 (P004)

E14. Demircan C, Evrensel T, Özkan L, Ursavaş A, Özkan A, Özcan V, Kurt E, Gönüllü G, Demiray M, Manavoğlu O. Acil servise başvuran akciğer kanserli hastaların analizi. Ulusal Kanser kongresi Antalya 2003 Bildiri Özetleri S32 (P033)

E15. Gönüllü G, Kurt E, Evrensel T, Kanat O, Demiray M, Arslan M, Gözkaman A, Manavoğlu O. Mide kanserinde second-line irinotekan monoterapisi: Klinik sonuçlarımız. Ulusal Kanser kongresi Antalya 2003 Bildiri Özetleri S83 (P192)

E16. Kanat O, Evrensel T, Demiray M, Balaban Adım Ş, vuruşkan H, Kurt E, Gönüllü G, Manavoğlu O. Olgu sunumu: Renal hemanjioperisitoma. Ulusal Kanser kongresi Antalya 2003 Bildiri Özetleri S177 (P1500)

G. Diğer Yayınlar

(Yukarıdaki maddelerde yer alan başlıklardaki kategorilere girmeyen ve belirtilmek istenen tüm eserler bu maddenin altında belirtilecektir.)

Uluslar arası bilimsel toplantılara davetli kanuşmacı:

G1. BIT's 10th Annual World Cancer Congress -2017 (WCC-2017) will be held on 19-21, May 2017 in Barcelona, Spain

G2. MODERNE ONKOLOGIE INTENSIV-SCHULUNG

Curcumin- , Vit. C-Hochdosis und weitere i.v. in Kombination mit Hyperthermie und Chemotherapie/Bestrahlung

Termin: Samstag 7. November 2015

Ort: Hotel Erzgiesserei Europe, Erzgiessereistraße 15, 80335 München

G3. 5. Kongress Für komplementäre krebstherapie

Ergebnisse der kombinierten Chemo-Curcumin-Therapie bei diversen ontologischen

Erkrankungen

G4. MODERNE ONKOLOGIE INTENSIV-SCHULUNG

Curcumin- , Vit. C-Hochdosis und weitere i.v. in Kombination mit Hyperthermie und Chemotherapie/Bestrahlung

Termin: Sa, 21. Februar 2015

Ort: Mercure Hotel Bochum City, Massenbergstraße 19-21, 44787 Bochum

G5. Annual Congress of the Korean Photodynamic Association

Curcumin and Cancer lecture

August 29, 2015

G6. Tumor Agnostic Era and personalized medicine (Roche sponsored)

(Georgia, 2018 July)

American Society of Oncology (ASCO)

European Association for Cancer Research

European Socienty of Hyperthermic Oncology (ESHO)

American Society of Clinical Oncology (ASCO)

Deutsche Gesellschaft für Hyperthermie e.V (GHT)

Türk Tıbbi Onkoloji Derneği